The Qdenga vaccine is indicated for people between the ages of 4 and 60; is the first aimed at those who have never had the disease
The National Health Surveillance Agency (Anvisa) approved, this Thursday 2, the registration of a new vaccine against dengue. The Qdenga immunizer, from the Takeda Pharma Ltda company, is the first intended for the population between 4 and 60 years of age.
In Brazil there is another vaccine aimed at fighting the disease, Dengue Axia, which can only be used by people between the ages of 9 and 45 who have already had the disease. Furthermore, it is only available in private healthcare facilities.
Qdenga consists of four different serotypes of the disease-causing virus and is available in a two-dose schedule, with a three-month interval between applications.
Efficiency
According to Anvisa, the vaccine showed an overall efficacy of 80.2% against dengue caused by any serotype and regardless of the underlying dengue serological status (seropositive and seronegative subjects) within 12 months of vaccine administration.
Qdenga has also been evaluated by the European Health Agency (EMA), having received a positive recommendation under the “EU Medicines for all” programme, a mechanism that allows for the evaluation of medicines intended for use in low- and middle-income countries income outside the European Union (EU). Marketing was approved in the European Union on December 20, 2022.
Source: Terra
Ben Stock is a lifestyle journalist and author at Gossipify. He writes about topics such as health, wellness, travel, food and home decor. He provides practical advice and inspiration to improve well-being, keeps readers up to date with latest lifestyle news and trends, known for his engaging writing style, in-depth analysis and unique perspectives.
